In a report released yesterday, Kenneth Goldman from J.P. Morgan maintained a Buy rating on Mondelez International (MDLZ – Research Report),

J.P. Morgan analyst Marcus Diebel maintained a Buy rating on Prosus (PROSF – Research Report) today. The company’s shares closed last Wednesday

NEW YORK - J.P. Morgan SE announced today that it has not undertaken any stabilization measures in connection with the recent securities offering by Caisse des Dépôts et Consignations (CDCEPS). The notice follows a prior announcement regarding the pre-stabilization period dated January 22,

The UK-headquartered bank is proposing to nearly halve the amount of money guaranteed to CEO CS Venkatakrishnan each year while capping his maximum pay package at £14.3m, Sky News can exclusively reveal.

Jan 16 (Reuters) - J.P.Morgan estimated spending on data centers could contribute between 10-20 basis points to U.S. economic growth in 2025-2026 as technology companies race to benefit from the ...

Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $368,287, and 3 were calls, valued at $221,926.

Ollie's Bargain Outlet Holdings (OLLI) gains after J.P. Morgan adds it to Analyst Focus List, predicts strong growth.

Whales with a lot of money to spend have taken a noticeably bearish stance on Morgan Stanley. If we consider the specifics of each trade, it is accurate to state that 12% of the investors opened trades with bullish expectations and 62% with bearish.

Can the upcoming J.P. Morgan Healthcare Conference next week trigger a flurry of biotech M&A deal making activity. Read more here.

In a report released today, Jeff Bernstein from Barclays maintained a Buy rating on Shake Shack (SHAK – Research Report), with a price target

In a report released today, Nick Dempsey from Barclays maintained a Sell rating on CD Projekt SA (OTGLF – Research Report), with a price target

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Boston Scientific Corp (NYSE:BSX) stands against the other medical AI stocks.